Lilly teams with Medtronic on Parkinson’s treatment
Eli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients' brains with an experimental drug for Parkinson’s disease.
Home » Search
Search Results
4,414 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Pentagon pulls plug on Rolls-Royce engine project
Congress and the General Electric/Rolls-Royce group that was developing the engine were notified of the termination decision Monday. Rolls-Royce had about 130 people, mostly engineers, working on the F-35 project in Plainfield and Indianapolis.
Company news
Bedford Regional Medical Center will receive a $46.8 million community facility direct loan from the U.S. Department of Agriculture to construct a new critical access hospital, according to an announcement from U.S. Sen. Dick Lugar’s office. Bedford Regional is owned by Indianapolis-based Indiana University Health, and is one of two hospitals in the southern Indiana town.
Indiana University Health ranked as the fourth-busiest transplant center in the nation, according to new data from the U.S. Organ Procurement and Transplantation Network. The Indianapolis-based hospital network performed 500 organ transplants last year, an uptick from 483 transplants in 2009. In three categories—intestine, pancreas and kidney-pancreas—IU Health ranked No. 1in the nation for volume of transplants. IU Health also ranked third in abdominal organ transplants, sixth in liver transplants, and ninth in kidney transplants. IU Health, formerly known as Clarian Health, has ranked as one of the nation’s top 10 busiest transplant centers since 2003.
A proposal that would have weakened Eli Lilly and Co.’s defenses against an unwanted takeover failed to pass April 18 despite a large majority of shareholders voting to remove those barriers for the second straight year. At the drugmaker’s annual shareholders meeting at its Indianapolis headquarters, 84.7 percent of the votes cast called for removing several provisions designed to prevent a hostile takeover of the company. However, Lilly’s bylaws require approval from 80 percent of all shares—whether voted or not—before removing the provisions. By that standard, only 72.6 percent of shares were voted in favor of removal. The vote tallies were nearly identical to those at last year’s meeting. For the past 25 years, Lilly has required the approval of 80 percent of the shareholders not only to approve hostile takeovers, but also to enact measures used to achieve them, such as removing directors before their terms end or expanding the size of the board. If the proposal had passed, such measures could have been approved by a bare majority of shareholders.
EDITORIAL: Township reform must not fail again
With property tax caps putting the squeeze on budgets, it’s foolhardy for townships to be sitting on millions that could be funding needed services.
Lilly gives $1M toward Marian medical school
Marian University needs to raise $120 million for its medical school and nursing programs. So far, the Catholic institution has raised $81 million.
Lilly shareholders fail to remove anti-takeover measures
A proposal that would have weakened Eli Lilly and Co.’s defenses against an unwanted takeover failed to pass Monday despite a large majority of shareholders voting to remove those barriers for the second straight year.
Analysts demand news on next Lilly blockbuster
Eli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just want to know when the next blockbuster will be coming.
Lilly shares falter after quarterly earnings report
Eli Lilly and Co.’s first-quarter profit beat the expectations of Wall Street analysts, but its stock price slipped anyway Monday morning, along with the broader market.
Charges drive down first-quarter profit at Lilly
First-quarter profit fell at Eli Lilly and Co. as the company recorded restructuring charges due to its downsizing and higher research costs as it tries to develop new drugs to help it shrug off its looming patent expirations.
FDA wants further testing of Lilly pancreas drug
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
Company news
Physicians, dentists, nurses, veterinarians, pharmacists and other medical workers would have to undergo a criminal background check when applying for a new state license under a bill approved Tuesday by an Indiana House of Representatives committee, according to the Associated Press. The House Public Health Committee voted 7-1 in favor of the bill, which would permit state boards to suspend, deny or revoke the licenses of people with criminal offenses determined to affect the person's ability to perform their duties. The Senate already has approved a version of the bill, which also would allow state boards to randomly select some seeking license renewals for criminal checks. Nearly 200,000 people are currently licensed or certified in one of the 20 professions specified in the bill. The bill allows action against a person's license if they've been convicted of various offenses, including illegal drug possession, fraudulently obtaining a controlled substance and sex crimes.
After two setbacks in the United States, Eli Lilly and Co. and Amylin Pharmaceuticals Inc. won the backing of European Union regulators for Bydureon, their once-weekly diabetes medicine. The London-based European Medicines Agency recommended Bydureon for approval in adults with Type 2 diabetes, according to a statement from the companies. The drug still must receive final approval from the European Commission. Bydureon is a long-acting version of Byetta, the twice-daily drug introduced by Indianapolis-based Lilly and San Diego-based Amylin in 2005. But Byetta has been losing sales to Denmark-based Novo Nordisk A/S's once-daily version of the medicine, Victoza, which has also been shown to be slightly more effective at reducing patients’ blood-sugar levels than Bydureon in a clinical trial. Lilly and Amylin had hoped to get Byrdureon approved a year ago. But the U.S. Food and Drug Administration delayed a decision in the spring and then in October demanded a new study of Bydureon’s effects on patients’ hearts. Lilly and Amylin expect to resubmit Bydureon to the FDA in the second half of this year. Analysts expect sales of Bydureon to top $1 billion a year and perhaps even approach $2 billion. Byetta had sales last year of $710 million, while Victoza rang up $450 million.
Indianapolis-based NICO Corp. won approval to sell its Myriad surgical device in Europe, the company reported last week. NICO can now sell its minimally invasive brain-tumor-removal device in the 27 countries that constitute the European Union. The Myriad device has been for sale in the United States since 2009 and has been used in more than 1,000 procedures, involving both adults and children. About 2 million people worldwide are diagnosed each year with a brain tumor.
Unusual North of South deal leaves taxpayers vulnerable
The $156 million North of South project is a complicated, risky and potentially transformative bet on downtown.
Dorson on leave amid fallout with executive committee
Roland Dorson, president of the Greater Indianapolis Chamber of Commerce, has had a falling out with the group’s executive committee and has gone on leave from the organization.
Indiana House speaker questions immigration crackdown
Indiana's Republican House speaker said Thursday he had concerns about aspects of a proposal calling for an Arizona-style crackdown on illegal immigration moving through the Legislature.
Firm joins race with IU autism drug
The Indiana University School of Medicine has licensed a pediatric psychiatrist’s patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.China making big gains in drug R&D jobs state covets
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
Wishard gives IT firms in health and life sciences a place to test products
TechPoint-led initiative is meant to help bring inventions to market by giving them a trial in real-world setting.
EDITORIAL: Rolls-Royce abatements worth the cost
We think city officials have made a compelling case for stepping up big to secure the future of one of Indianapolis’ largest employers.
Tax breaks approved for bioanalytical lab operator
The Metropolitan Development Commission on Wednesday preliminarily approved Advion BioServices Inc.’s request for a tax abatement to build a laboratory at Purdue Research Park in Indianapolis.